Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (IRIS)

27 de octubre de 2026 actualizado por: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase II Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (The IRIS Trial: Immune Checkpoint Inhibitor Rechallenge Involving Sarilumab)

The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

41

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Danielle Wendler
  • Número de teléfono: 410-502-5140
  • Correo electrónico: JHCTN@jhmi.edu

Copia de seguridad de contactos de estudio

  • Nombre: Chelsea Miralles
  • Número de teléfono: 410-955-9923
  • Correo electrónico: cmirall1@jhmi.edu

Ubicaciones de estudio

    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
        • Contacto:
          • Danielle Wendler
          • Número de teléfono: 410-502-5140
          • Correo electrónico: JHCTN@jhmi.edu
        • Contacto:
          • Chelsea Miralles
          • Número de teléfono: 4109559923
          • Correo electrónico: cmirall1@jhmi.edu
        • Investigador principal:
          • Aliyah Pabani, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Eligible patients include patients with malignancy treated with ICI, who have been diagnosed with a clinically significant irAE (grade 1-3 attributed to ICI per CTCAE v6.0) requiring interruption of ICI by the treating physician. This study is limited to patients with the following specific irAEs as IL-6R blockade has demonstrated effectiveness in these conditions. Specific toxicities eligible for inclusion are; arthritis, colitis, PMR, nephritis, pneumonitis, hepatitis, myositis

  • The risk/benefit profile must favor ICI rechallenge as deemed per treating oncologist

  • The irAE must have improved to grade 1 by CTCAE criteria v6.0 for at least 1 week (exception for patients who have endocrinopathies which will typically require lifelong hormone supplementation)

  • Be willing and able to provide informed consent/assent for the trial

  • Be ≥18 years of age on the day of signing informed consent

  • Female subject of childbearing potential must have a negative urine or serum pregnancy test within 2 weeks prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • Women of child-bearing potential (WOCBP):

    • Agree to use contraception while participating in this study, and for a period of 6 months following last dose of Sarilumab or ICI, as effects of these agents on the developing human fetus are unknown. Men whose partner is a WOCBP must also agree to use contraception during this period. Negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within two weeks of registration. Women must not be breastfeeding or plan to breastfeed for the duration of therapy or 6 months after.
  • Males must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 3 months after last dose of sarilumab, 120 days even if he has undergone a successful vasectomy

  • Have adequate organ function as described below

    • Absolute neutrophil count (ANC) ≥500/mm3
    • Platelets ≥ 50,000/mm3
    • AST/ALT <=3× institutional upper limit of normal
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  • Completed informed consent process, including signing Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form.

  • Willing and able to comply with clinical trial instructions and requirements. Subjects must be competent to report AEs, understand the drug dosing schedule, and use of medications to control AEs

Exclusion Criteria:

  • History of grade 4 irAE (attributed to ICI per CTCAE v6.0)
  • History of cardiovascular or neurologic immune related adverse event
  • Active or serious infections
  • History of latent Tuberculosis (TB) or uncontrolled hepatitis B/C
  • History of gastrointestinal perforation or diverticulitis
  • Severe hepatic impairment (AST, ALT >3xULN; total bilirubin >1.5xULN)
  • Significant hematological abnormalities
  • On prednisone equivalent >10mg prior to first dose of trial treatment
  • History of immunodeficiency disorder
  • Treatment with a non-biologic immunosuppressive or immune-modulating drug (e.g. methotrexate, azathioprine, mycophenolate, cyclosporine, hydroxychloroquine, penicillamine) at time of enrollment
  • Treatment with other immune-modulating biologic agents (e.g TNF-alpha inhibitors) within 8 weeks prior to enrollment
  • History of anaphylaxis or IgE-mediated hypersensitivity to sarilumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to sarilumab.
  • The subject must meet all of the inclusion criteria and none of the exclusion criteria.

No eligibility waivers will be granted.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Sarilumab with ICI

Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be dosed by investigator's choice per standard of care for malignancy. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator.

Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks.

ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety as assessed by Absence of any grade ≥2 Immune Related Adverse Event (irAE)
Periodo de tiempo: From enrollment to the end of treatment at 53 weeks

Absence of any grade ≥2 Immune Related Adverse Event (irAE) in the 3 months after ICI rechallenge, defined as grade ≥2 adverse event attributed to ICI by CTCAE v6.0

From enrollment to the end of treatment at 53 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and tolerability as assessed by occurrence of adverse events
Periodo de tiempo: From enrollment to the end of treatment at 53 weeks

Safety and tolerability will be measured by occurrence of grade ≥3 adverse events as measured by CTCAE v6.0 and patient reported outcomes (PROs) as assessed by PRO-CTCAE v1.0.

From enrollment to the end of treatment at 53 weeks
Absence of Serious immune-related adverse event
Periodo de tiempo: From enrollment to the end of treatment at 53 weeks

To assess to the safety of Immune Checkpoint Inhibitor (ICI) rechallenge with sarilumab with respect to serious irAE of grade ≥2 in patients with a history of non- cardiovascular and non-neurologic clinically significant irAEs.

From enrollment to the end of treatment at 53 weeks
Efficacy as assessed by progression free survival
Periodo de tiempo: From enrollment to the end of treatment at 53 weeks

Cancer outcomes will be measured by progression free survival (PFS). PFS is defined as the time from first dose of sarilumab + ICI rechallenge until investigator-assessed radiological progressive disease (PD) or death, whichever comes first.

From enrollment to the end of treatment at 53 weeks
Efficacy as assessed by Overall survival
Periodo de tiempo: From enrollment to the end of treatment at 53 weeks

Cancer outcomes will be measured by overall survival (OS).Overall survival is defined as the time from first dose of sarilumab + ICI rechallenge until death.

From enrollment to the end of treatment at 53 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Aliyah Pabani, MD, Johns Hopkins University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de agosto de 2029

Finalización del estudio (Estimado)

1 de diciembre de 2029

Fechas de registro del estudio

Enviado por primera vez

17 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de septiembre de 2026

Publicado por primera vez (Actual)

23 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • J2687
  • 15845 (Otro número de subvención/financiamiento: Robert A. Winn Excellence in Clinical Trials Award)
  • IRB00559848 (Otro identificador: Johns Hopkins IRB)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir